WO2021229188A1 - Nouveaux composés fluorescents pour le marquage de tissu tumoral - Google Patents
Nouveaux composés fluorescents pour le marquage de tissu tumoral Download PDFInfo
- Publication number
- WO2021229188A1 WO2021229188A1 PCT/FR2021/050832 FR2021050832W WO2021229188A1 WO 2021229188 A1 WO2021229188 A1 WO 2021229188A1 FR 2021050832 W FR2021050832 W FR 2021050832W WO 2021229188 A1 WO2021229188 A1 WO 2021229188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chem
- compounds
- compound
- tumor
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 74
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 72
- 238000002372 labelling Methods 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000001356 surgical procedure Methods 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 7
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000002059 diagnostic imaging Methods 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 18
- 229960004657 indocyanine green Drugs 0.000 description 18
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000012429 reaction media Substances 0.000 description 6
- -1 2,2-dimethylbutyl Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- JWUQFQYYMGMPKE-UHFFFAOYSA-N 2-chloro-3-(hydroxymethylidene)cyclohexene-1-carbaldehyde Chemical compound OC=C1CCCC(C=O)=C1Cl JWUQFQYYMGMPKE-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YQWPHBFLHAJVCG-UHFFFAOYSA-N 3-(4-sulfanylphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(S)C=C1 YQWPHBFLHAJVCG-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- WXOHKMNWMKZMND-UHFFFAOYSA-N 4-aminohydrocinnamic acid Chemical compound NC1=CC=C(CCC(O)=O)C=C1 WXOHKMNWMKZMND-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 C*CCCCN(C(C1(C)C)=CC=C(CCC2)C(Sc3ccc(CC*)cc3)=C2C=CC(C2(C)C)=*(CCCCS(O)(=O)=O)c(cc3)c2c(cc2)c3cc2S(O)(=O)=O)c2c1c1ccc(*)cc1cc2 Chemical compound C*CCCCN(C(C1(C)C)=CC=C(CCC2)C(Sc3ccc(CC*)cc3)=C2C=CC(C2(C)C)=*(CCCCS(O)(=O)=O)c(cc3)c2c(cc2)c3cc2S(O)(=O)=O)c2c1c1ccc(*)cc1cc2 0.000 description 1
- FXVMRKBTKKLDFH-UHFFFAOYSA-N CC1=C(CCCCS(O)(=O)=O)C(C2=C(C=C3)C(S([O-])(=O)=O)=CC=C2)=C3[N+]1(C)C Chemical compound CC1=C(CCCCS(O)(=O)=O)C(C2=C(C=C3)C(S([O-])(=O)=O)=CC=C2)=C3[N+]1(C)C FXVMRKBTKKLDFH-UHFFFAOYSA-N 0.000 description 1
- JKNCPHZDTACFRM-UHFFFAOYSA-N CC1=C(CCCCS(O)(=O)=O)C(C2=C(C=C3OCCCCCC([O-])=O)C(S(O)(=O)=O)=CC=C2)=C3[N+]1(C)C Chemical compound CC1=C(CCCCS(O)(=O)=O)C(C2=C(C=C3OCCCCCC([O-])=O)C(S(O)(=O)=O)=CC=C2)=C3[N+]1(C)C JKNCPHZDTACFRM-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Definitions
- the present invention relates to novel fluorescent compounds which can be used for labeling tumor tissue, their method of preparation, as well as their application as a tool for monitoring, diagnosing or assisting in cancer surgery.
- Fluorescent compounds have been used for over fifty years in medicine as markers in non-invasive imaging techniques for monitoring and / or diagnosis.
- Certain existing fluorescent markers have a limited persistence of fluorescence, which makes it necessary to operate on the patient following the injection of the marker and does not make it possible to obtain a satisfactory delineation of the tissue. tumor. In other cases, the accumulation of the label in the tissues is not high enough, which leads to poor labeling and therefore detection problems. The localization of lesions or tumors then their elimination, for example by surgery, is then not complete.
- ICG indocyanine green
- Another major drawback of existing compounds is that they cannot be used directly. In fact, in order to be used, they need to be coupled with other targeting molecules such as antibodies, proteins, molecules specific to tumor tissue, folic acid, or even steroids.
- the present invention overcomes the problems of the prior art explained above by providing fluorescent molecules having a preferential distribution in tumor tissues over healthy tissues and sufficient persistence for their use in techniques of. imaging for monitoring, diagnosis, and / or surgical assistance.
- These new molecules have the major advantage of being able to be used alone and directly, without prior coupling, due to their specific affinity for tumor tissue. They also have, compared to the molecules of the prior art, a much higher remanence in the tumor tissues, going up to a duration of several days, which allows a more extensive elimination of these fluorescent molecules circulating outside the tumor tissues, and thus improved visualization thanks to a better signal-to-noise ratio.
- the present invention relates to a compound of formula (I) [Chem. 1] where n1 and n2 are each an integer from 0 to 15,
- Ri, R2, R3, R4, R5 and He are each independently selected from H, OH, SH, NH 2 , SO3R10 and X-R11-Y,
- R11, R'11, R ”n being independently selected from C1 to C15 alkyl, aryl, heteroaryl, (C1 to Cis alkyl) aryl, (C1 to Cis alkyl) heteroaryl, aryl (C1 to C15 alkyl) and heteroaryl (C1-C15 alkyl);
- Y, Y ’, Y being independently selected from H, halogen, COOR’10 or amide; R7 and Re being each selected from H, OH, SH, NH2, C1-C15 alkyl, and X'-R'n-Y ';
- R 9 being chosen from H, OH, SH, NH2 and X ”-R” nY ”, said compound comprising at least one group X-R11-Y, X'-R'n-Y 'or X” -R ”n - Y ”with Y, Y ', and / or Y” which is COOR'10.
- the present invention also relates to the process for preparing the compounds of formula (I) according to the invention, as well as the process for labeling tumor tissue with one of the compounds according to the invention or prepared according to the process of the invention. .
- the first subject of the present invention relates to a compound of formula (I)
- ni and n2 are each an integer from 0 to 15, Ri, R2, R3, R4, R6 and R6 are each independently selected from H, OH, SH, NH 2 , SO3R10 and X-R11-Y,
- X, X ’, X being independently O, S or NH,
- R11, R'11, R ”H being independently selected from C1 to C15 alkyl, aryl, heteroaryl, (C1 to C18 alkyl) aryl, (C1 to Cis alkyl) heteroaryl, aryl (C1 to C15 alkyl) and heteroaryl (C1-C15 alkyl);
- Y, Y ’, Y being independently selected from H, halogen, COOR’10 or amide;
- R7 and R8 being each selected from H, OH, SH, NH2, C1-C15 alkyl, and X'-R'n-Y '; R 9 being chosen from H, OH, SH, NH2 and X ”-R” nY ”, said compound comprising at least one X-R11-Y, X'-R'n-Y 'or X” -R ”n group - Y ”with Y, Y ', and / or Y” which is COOR'10.
- C 1 to C 15 alkyl means a hydrocarbon chain, cyclic, linear or branched, containing from 1 to 15 carbon atoms, preferably from 2 to 6 carbon atoms and more preferably still from 4 to 6 carbon atoms, in particular 5 carbon atoms and possibly being in particular a methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl chain, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, isopentyl, neopentyl, 2-pentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, heptyl, octyl, nonyl, decyl, dodecyl, palmityl.
- heptyl octyl
- heteroaryl means an aromatic group, containing one or more aromatic rings, optionally substituted, and comprising at least one heteroatom other than carbon and hydrogen.
- arylalkyl is understood to mean an aryl group substituted by one or more alkyl groups, said alkyl groups possibly being C1 to C15 alkyl groups, preferably containing from 1 to 15 carbon atoms. carbon.
- heteroarylalkyls is understood to mean a heteroaryl group substituted by one or more alkyl groups, said alkyl groups possibly being C 1 to C 15 alkyl groups, preferably containing from 1 to 15 carbon atoms. carbon.
- m or n2 are independently of one another, equal to 1, 2, 3, 4 or 5, more preferably still 3 or 4.
- n-i n2 and is preferably equal to 1, 2, 3, 4 or 5, more preferably still 3 or 4.
- the molecule is symmetrical.
- it comprises a single group X ”-R” nY ”with Y” which is COOR'10 which is carried by R9 and / or 2 groups X-R11-Y with Y which is COOR'10, one carried by one of Ri, R2, R30U Rz, preferably one of Ri, R2 or R3 and the other carried by one of R4, Rs, R6 or Rs, preferably one of R4, Rs or R6.
- R10, and / or R'10 may be identical.
- X, X ', and / or X may be the same, Y, Y', and / or Y” may be the same, Ru, R'11, and / or R ”n may be the same.
- the compounds according to the invention can in particular be chosen from the compounds of the following general formula: for which X ”can be O, S or NH, then corresponding to the formulas below:
- the compounds of formula (I) according to the invention can in particular be chosen from the compounds of formula (I) for which Ri, R2, R3, R4, Rs and Re ne are not all simultaneously H, which in this case excludes the compounds according to formula (II) below:
- the compound of formula (I) according to the invention can preferably be chosen from the compounds of the following general formulas:
- the compounds according to the invention can be chosen from the compounds of the following formulas [Chem. 5] [Chem. 7] in which R1, R2, R3, R4, Rs, Re, R7, Rs and R9 are as defined above. According to a preferred embodiment, the compounds according to the invention can be chosen from the following compounds:
- the second object of the present invention relates to the process for preparing the compounds of formula (I) according to the invention comprising a reaction step between:
- the third object of the invention relates to the method of labeling tumor tissue with one of the compounds according to the invention or prepared according to the method of the invention.
- tumor tissue is understood to mean the tissue consisting of tumor cells which are abnormal proliferative cells, and supporting tissue, also called tumor stroma or interstitial tissue, made up of cells and extra-cellular material in which the tumor vasculature is located.
- the fluorescent compounds according to the invention have the particularity, after their diffusion in the body, of being trapped in the tumor tissue, while they are eliminated from healthy tissue. This feature makes it possible to use these fluorescent compounds directly, without prior coupling to another labeling molecule, thus making their use simpler, faster and more efficient than that of the compounds of the prior art. It has been observed that this elimination from healthy tissue increases over time. In general, between 24 and 72 hours, preferably between 36 and 60 hours and more preferably 48 hours after the administration of these compounds, their elimination from healthy tissues is complete. However, they remain trapped in tumor tissue. This property makes it possible to have a clear differentiation of tumor tissues from healthy tissues and thus the use of these compounds in monitoring, diagnostic and / or surgical assistance applications in the context of cancerous diseases. This differentiation lasts for 6 to 48 hours, preferably 12 to 36 hours, making it possible to program the diagnosis or the surgery in a targeted manner.
- the compounds according to the invention can thus in particular be used in the context of cancers, for example hormone-dependent, such as breast cancer or digestive cancers, such as pancreatic cancer.
- hormone-dependent such as breast cancer
- digestive cancers such as pancreatic cancer.
- pancreatic cancer tumors are particularly difficult to remove in their entirety by surgery because they are not easily delimited.
- the use of the compounds according to the invention makes it possible to obtain a better visualization of the contours of the tumors thanks to the differentiation of labeling between the tumor tissue and the healthy tissue, and thus a more efficient tumor resection by surgery.
- the invention also relates to the use of one of the compounds according to the invention or prepared according to the method of the invention in a method of labeling tumor tissue.
- This method of labeling tissues requires the administration of the compounds intravenously, intraarterially, or into another vessel, in particular a lymphatic vessel, either by local injection or by local application, preferably intravenously.
- Another object of the invention relates to a composition
- a composition comprising one of the compounds according to the invention or prepared according to the process of the invention and at least one pharmaceutically acceptable adjuvant.
- the invention also relates to one of the compounds according to the invention or prepared according to the process of the invention or a composition comprising one of the compounds according to the invention or prepared according to the process of the invention for its use. in a method of labeling and / or detecting tumor tissue, and / or in the surgical treatment of tumors.
- the invention also relates to a method of detecting tumor tissue comprising a step of labeling tumor tissue with one of the compounds according to the invention or prepared according to the method of the invention, and a step of detection by medical imaging in fluorescence or fluorescence spectrometry.
- FIG. 1 shows the median values and standard deviations of the tumor / abdomen intensity ratios as a function of post-injection times of Compound 2 (CJ215) and ICG.
- FIG. 2 shows the results of ex vivo imaging of pancreatic tumors after injection of two compounds according to the invention and a fluorescent agent of the prior art (ICG).
- the reaction medium is cooled to room temperature and the precipitate is separated by filtration and washed with diethyl ether to provide 4.33 g (yield: 43.9%) of a green solid.
- the crude product is purified by flash column chromatography (reverse phase C18 silica gel, 0-25% acetonitrile / water).
- Example 8 Comparison of a compound according to the invention and of a fluorescent agent of the prior art (ICG) for in vivo imaging of mammary tumors
- ICG fluorescent agent of the prior art
- ICG or indocyanine green / Infracyanine
- ICG is a fluorescent agent of the prior art, already approved for use in humans for the evaluation of cardiac and hepatic functions, as well as in ophthalmology, for retinal pathologies. It is also being evaluated in numerous clinical trials around the world for guiding the surgical procedure during tumor resection, or the mapping of lymph nodes draining tumors, by near infrared imaging.
- the ICG was compared with the compound (2) according to the invention, the synthesis of which is described in the preceding example 2, this compound is called CJ215 in this study.
- the study included a total of 30 mice divided into three groups.
- the tumor grafts were all carried out with 50,000 4T1-Dendra2 / 20 ⁇ l cells injected into 2 mammary glands contralateral for each of the mice.
- the injections of biomarkers (compound 2 called CJ215 in this study and ICG) were carried out on D9 post-tumor grafting (in order to limit the appearance of necrosis in tumors).
- the change in the intensity of the fluorescence signals observed for each of the biomarkers over time was evaluated by microscopic image.
- the ability of the two markers to produce a signal specifically localized to the tumor was assessed quantitatively by calculating the ratio of the specific signal bound to the tumor to the non-specific signal in the surrounding tissues.
- the imaging protocol was carried out at times 2h, 24h, 48h, 4 and 6 days post-injection for all the mice. All the images produced at each acquisition time were acquired on an I VIS Spectrum imager (Perkin Elmer) with the following parameters:
- the quantitative measurements were carried out on the non-deconvoluted raw images.
- the acquisition time was set in automatic mode. In this mode, the system determines the acquisition time necessary to reach the imposed target value (6000 counts) within the allotted time (fixed at 2 min).
- Figure 1 reports the median values and standard deviations of the tumor / abdomen intensity ratios as a function of post-injection times of CJ215 and ICG.
- Example 9 Comparison of two compounds according to the invention and of a fluorescent agent of the prior art (ICG) in ex vivo imaging of pancreatic tumors.
- a model of orthotopic pancreatic adenocarcinoma in mice has been developed. Tumor cells were amplified subcutaneously in SCID mice and the resulting fragments were then surgically implanted into the pancreas of irradiated BALB / c nude mice.
- MRI 4.7T, PharmaScan, Bruker Biospin
- Animals were subjected to weak fluorescence in order to minimize autofluorescence. Fluorescent imaging was performed with a charge coupled device (CCD) camera (PhotonRT, BiospaceLab) with excitation at 700 nm and emission filter at 770 nm.
- CCD charge coupled device
- ex vivo fluorescent images were acquired.
- the fluorescent compounds according to the invention 2 (CJ215) and CJ319 (the structure of which is detailed below) were injected intravenously at 2 mg / kg, 39 days after implantation of the tumor fragments, while the volumes average tumors were about 70 mm 3 .
- Indocyanine green (ICG) a dye widely used in intraoperative tumor imaging, was included as a control.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227043701A KR20230010713A (ko) | 2020-05-15 | 2021-05-12 | 종양 조직 표지를 위한 새로운 형광 화합물 |
JP2023514171A JP2023525601A (ja) | 2020-05-15 | 2021-05-12 | 腫瘍組織を標識するための新規蛍光化合物 |
CN202180035401.9A CN115605459A (zh) | 2020-05-15 | 2021-05-12 | 用于标记肿瘤组织的新型荧光化合物 |
CA3178232A CA3178232A1 (fr) | 2020-05-15 | 2021-05-12 | Nouveaux composes fluorescents pour le marquage de tissu tumoral |
BR112022023154A BR112022023154A2 (pt) | 2020-05-15 | 2021-05-12 | Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição |
EP21732450.8A EP4149925A1 (fr) | 2020-05-15 | 2021-05-12 | Nouveaux composés fluorescents pour le marquage de tissu tumoral |
US17/925,434 US20230203014A1 (en) | 2020-05-15 | 2021-05-12 | Novel fluorescent compounds for labeling tumor tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2004868 | 2020-05-15 | ||
FR2004868A FR3110165B1 (fr) | 2020-05-15 | 2020-05-15 | Nouveaux composés fluorescents pour le marquage de tissu tumoral |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021229188A1 true WO2021229188A1 (fr) | 2021-11-18 |
Family
ID=72644317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2021/050832 WO2021229188A1 (fr) | 2020-05-15 | 2021-05-12 | Nouveaux composés fluorescents pour le marquage de tissu tumoral |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230203014A1 (fr) |
EP (1) | EP4149925A1 (fr) |
JP (1) | JP2023525601A (fr) |
KR (1) | KR20230010713A (fr) |
CN (1) | CN115605459A (fr) |
BR (1) | BR112022023154A2 (fr) |
CA (1) | CA3178232A1 (fr) |
FR (1) | FR3110165B1 (fr) |
WO (1) | WO2021229188A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114751907A (zh) * | 2022-03-17 | 2022-07-15 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014101339A1 (fr) * | 2012-12-28 | 2014-07-03 | 浙江海正药业股份有限公司 | Composé colorant cyanine et son procédé de préparation, et agent à double fonction pour thérapie photodynamique et son procédé de préparation |
-
2020
- 2020-05-15 FR FR2004868A patent/FR3110165B1/fr active Active
-
2021
- 2021-05-12 BR BR112022023154A patent/BR112022023154A2/pt unknown
- 2021-05-12 US US17/925,434 patent/US20230203014A1/en active Pending
- 2021-05-12 CN CN202180035401.9A patent/CN115605459A/zh active Pending
- 2021-05-12 WO PCT/FR2021/050832 patent/WO2021229188A1/fr unknown
- 2021-05-12 KR KR1020227043701A patent/KR20230010713A/ko unknown
- 2021-05-12 CA CA3178232A patent/CA3178232A1/fr active Pending
- 2021-05-12 EP EP21732450.8A patent/EP4149925A1/fr active Pending
- 2021-05-12 JP JP2023514171A patent/JP2023525601A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014101339A1 (fr) * | 2012-12-28 | 2014-07-03 | 浙江海正药业股份有限公司 | Composé colorant cyanine et son procédé de préparation, et agent à double fonction pour thérapie photodynamique et son procédé de préparation |
Non-Patent Citations (4)
Title |
---|
HUIYUAN ZHANG ET AL: "A Versatile Prodrug Strategy to In Situ Encapsulate Drugs in MOF Nanocarriers: A Case of Cytarabine-IR820 Prodrug Encapsulated ZIF-8 toward Chemo-Photothermal Therapy", ADVANCED FUNCTIONAL MATERIALS, vol. 28, no. 35, 1 July 2018 (2018-07-01), DE, pages 1802830, XP055764974, ISSN: 1616-301X, DOI: 10.1002/adfm.201802830 * |
MICHAEL P. A. WILLIAMS ET AL: "Synthesis, Photophysical, Electrochemical, Tumor-Imaging, and Phototherapeutic Properties of Purpurinimide- N -substituted Cyanine Dyes Joined with Variable Lengths of Linkers", BIOCONJUGATE CHEMISTRY, vol. 22, no. 11, 16 November 2011 (2011-11-16), pages 2283 - 2295, XP055271457, ISSN: 1043-1802, DOI: 10.1021/bc200345p * |
SAKKARAPALAYAM M MAHALINGAM ET AL: "Supplementary Information Evaluation of Novel Tumor-Targeted Near-Infrared Probe for Fluorescence-Guided Surgery of Cancer", 8 October 2018 (2018-10-08), XP055765038, Retrieved from the Internet <URL:https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b01115/suppl_file/jm8b01115_si_001.pdf> [retrieved on 20210114] * |
VAN DER WAL STEFFEN ET AL: "Synthesis and systematic evaluation of symmetric sulfonated centrally CC bonded cyanine near-infrared dyes for protein labelling", DYES AND PIGMENTS, ELSEVIER APPLIED SCIENCE PUBLISHERS BARKING, GB, vol. 132, 20 April 2016 (2016-04-20), pages 7 - 19, XP029566721, ISSN: 0143-7208, DOI: 10.1016/J.DYEPIG.2016.03.054 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114751907A (zh) * | 2022-03-17 | 2022-07-15 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
KR20230010713A (ko) | 2023-01-19 |
CN115605459A (zh) | 2023-01-13 |
BR112022023154A2 (pt) | 2023-02-07 |
EP4149925A1 (fr) | 2023-03-22 |
FR3110165B1 (fr) | 2022-10-28 |
FR3110165A1 (fr) | 2021-11-19 |
US20230203014A1 (en) | 2023-06-29 |
JP2023525601A (ja) | 2023-06-16 |
CA3178232A1 (fr) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2350355C2 (ru) | Флюоресцентный контрастирующий агент ближней инфракрасной области спектра и способ флуоресцентной томографии | |
JP6073961B2 (ja) | 蛍光リン脂質エーテル化合物、組成物、及びその使用 | |
CN111362971B (zh) | 靶向psma的双苯并噻二唑类化合物及其制备方法与应用 | |
US9801960B2 (en) | Probe for a biological specimen and labelling method and screening method using the probe | |
JPH11501914A (ja) | 光化学治療における光増感剤としての5−アミノレブリン酸のエステル | |
CN1328471A (zh) | 近红外荧光造影剂和荧光成像 | |
JP2003517025A (ja) | 近赤外蛍光造影剤及び蛍光イメージング | |
US20110165085A1 (en) | Tumor selective fluorescent staining agent | |
WO2021229188A1 (fr) | Nouveaux composés fluorescents pour le marquage de tissu tumoral | |
JP2010203966A (ja) | 低酸素領域イメージング用近赤外蛍光プローブ | |
US20130095520A1 (en) | Method for detection of urothelial cancer | |
CN113597547B (zh) | 细胞和组织内脂滴的荧光成像试剂 | |
EP3772528A1 (fr) | Utilisation de composés fluorophores de type aza-bodipy comme agents de contraste dans l'infrarouge très lointain | |
JP2005120026A (ja) | 近赤外蛍光造影剤 | |
JPWO2005061456A1 (ja) | 近赤外蛍光造影剤 | |
WO2022202863A1 (fr) | Composition d'imagerie de contraste contre le cancer | |
Zhang et al. | Dynamic monitoring of the fibrosis disease by a collagen targeting near infrared probe | |
EP2643296B9 (fr) | Derives fluorescents de cyanines polyamines en tant que sonde de diagnostic | |
CN116731708A (zh) | 一种花青染料和白蛋白的组合物及其制备方法和应用 | |
JP2005145819A (ja) | 蛍光造影剤および体外蛍光造影方法 | |
JP2005170812A (ja) | 蛍光造影剤及び蛍光造影方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21732450 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3178232 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023514171 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022023154 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227043701 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021732450 Country of ref document: EP Effective date: 20221215 |
|
ENP | Entry into the national phase |
Ref document number: 112022023154 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221114 |